Medivir to present at Redeye Growth Day
Medivir (NASDAQ: MVIR), a pharmaceutical company specializing in oncology, announced its participation at Redeye Growth Day on May 30, 2024. CEO Jens Lindberg will present updated data from the ongoing phase 1b/2a clinical trial of fostroxacitabine bralpamide (fostrox) and future development plans at 09:40 CET. The presentation will be live-streamed and available for replay on the event page and Medivir's website.
Medivir focuses on developing innovative treatments for cancers with high unmet medical needs. Their lead candidate, fostrox, is designed to selectively target liver cancer cells, potentially offering significant patient benefits.
- Medivir's participation in Redeye Growth Day increases visibility among investors.
- CEO Jens Lindberg will present updated data from an important clinical trial.
- Fostroxacitabine bralpamide (fostrox) shows potential in treating liver cancer.
- Live broadcasting of the presentation enhances accessibility for potential investors.
- Medivir's focus on high unmet medical needs positions the company as a leader in innovative cancer therapies.
- The success of Medivir heavily relies on the development and approval of fostrox.
- No revenue or financial performance updates were provided in the announcement.
- The clinical trial is still in phase 1b/2a, indicating it is at an early stage and subject to risks.
- Increasing expenses and financial reliance on a single product may impact shareholders.
CEO Jens Lindberg will present updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and the development plans moving forward at 09.40 CET.
The presentation is live broadcasted and can be followed at the event page, where the replay and the presentations will be available afterwards; https://www.redeye.se/events/981085/redeye-growth-day-2024
The presentation will also be available after the meeting on Medivirs website; www.medivir.com.
For additional information, please contact
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-redeye-growth-day,c3991569
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-redeye-growth-day-302159105.html
SOURCE Medivir
FAQ
What is Medivir presenting at Redeye Growth Day?
When is Medivir's presentation at Redeye Growth Day?
How can I watch Medivir's presentation at Redeye Growth Day?
What is Medivir's focus in cancer treatment?
What is fostroxacitabine bralpamide (fostrox)?
Where can I find the replay of Medivir's presentation?
